|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:activeIngredient
|
gptkb:hydrocodone_bitartrate
|
|
gptkbp:approvalYear
|
October 2013
|
|
gptkbp:ATCCode
|
N02AA03
|
|
gptkbp:blackBoxWarning
|
addiction, abuse, and misuse
life-threatening respiratory depression
neonatal opioid withdrawal syndrome
|
|
gptkbp:brand
|
gptkb:Zohydro_ER
|
|
gptkbp:contraindication
|
paralytic ileus
acute or severe bronchial asthma
known hypersensitivity to hydrocodone
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
capsule
extended-release capsule
|
|
gptkbp:genericAvailable
|
no (as of 2024)
|
|
gptkbp:genericName
|
hydrocodone bitartrate extended-release
|
|
gptkbp:halfLife
|
approximately 5-6 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zohydro ER
|
|
gptkbp:indication
|
pain management
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Zogenix
|
|
gptkbp:marketedAs
|
gptkb:Zogenix
2014
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notableFeature
|
first extended-release hydrocodone-only product
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:riskFactor
|
addiction
overdose
respiratory depression
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
constipation
dizziness
fatigue
drowsiness
|
|
gptkbp:storage
|
20°C to 25°C (68°F to 77°F)
|
|
gptkbp:strengthsAvailable
|
10 mg
20 mg
40 mg
50 mg
15 mg
30 mg
|
|
gptkbp:bfsParent
|
gptkb:Hydrocodone
|
|
gptkbp:bfsLayer
|
7
|